The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

Phase 3

• Conditions: Osteoporosis

• Registration Number: NCT00346190
• Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Brief Summary

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Status Verified: 2006-01
• Study First Submitted: 2006-06-27
• Study First Submitted QC: 2006-06-27
• Study First Posted: 2006-06-29
• Study Completion: 2007-04
• Last Update Submitted: 2007-04-11
• Last Update Posted: 2007-04-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Male and Female aged > 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent

Exclusion Criteria

• Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium> 2.65 mmol/L Treatment with any investigational drug within the last 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Mcgill University Health center; 🇨🇦 Montreal, Quebec, Canada